| Literature DB >> 24752207 |
Edwin M Posadas1, Robert A Figlin1.
Abstract
Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24752207 DOI： 10.1038/nrurol.2014.89
Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432